Your browser doesn't support javascript.
loading
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies.
Jiménez, Moraima; Roldán, Elisa; Fernández-Naval, Candela; Villacampa, Guillermo; Martinez-Gallo, Mónica; Medina-Gil, Daniel; Peralta-Garzón, Soraya; Pujadas, Gemma; Hernández, Cristina; Pagès, Carlota; Gironella, Mercedes; Fox, Laura; Orti, Guillermo; Barba, Pere; Pumarola, Tomás; Cabirta, Alba; Catalá, Eva; Valentín, Mercedes; Marín-Niebla, Ana; Orfao, Alberto; González, Marcos; Campins, Magda; Ruiz-Camps, Isabel; Valcárcel, David; Bosch, Francesc; Hernández, Manuel; Crespo, Marta; Esperalba, Juliana; Abrisqueta, Pau.
Afiliação
  • Jiménez M; Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Roldán E; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Fernández-Naval C; Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Villacampa G; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Martinez-Gallo M; Department of Microbiology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Medina-Gil D; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Peralta-Garzón S; Department of Immunology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Pujadas G; Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UA), Barcelona, Spain.
  • Hernández C; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Pagès C; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/Natzaret, Barcelona, Spain.
  • Gironella M; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Fox L; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/Natzaret, Barcelona, Spain.
  • Orti G; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Barba P; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/Natzaret, Barcelona, Spain.
  • Pumarola T; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Cabirta A; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/Natzaret, Barcelona, Spain.
  • Catalá E; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Valentín M; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/Natzaret, Barcelona, Spain.
  • Marín-Niebla A; Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Orfao A; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • González M; Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Campins M; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Ruiz-Camps I; Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Valcárcel D; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Bosch F; Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Hernández M; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Crespo M; Department of Microbiology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Esperalba J; Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Abrisqueta P; Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Blood Adv ; 6(3): 774-784, 2022 02 08.
Article em En | MEDLINE | ID: mdl-34844263
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / COVID-19 Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / COVID-19 Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article